Thousand Oaks drug maker Amgen Inc. has inked an agreement with a German pharmaceutical company to research products. Heidelberg-based Graffinity Pharmaceuticals will receive technology access fees and success payments for the generation of small molecule hits against a range of drug targets. Amgen, in turn, will have access to the company’s proprietary fragment-based drug discovery technology.
